 The purpose of this study is to evaluate the percentage of subjects in Australian clinical practice continuing treatment with Anakinra Kineret at the end of study week 48 in subjects with active RA. The continued use of Kineret will be based on pre-defined response assessment criteria for subjects with active RA. 